Novo Nordisk
75 Hayden Avenue
Lexington
MA
02421
United States
Tel: 617-612-6200
Website: https://www.novonordisk-us.com/
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.
Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.
CONNECT
Novo Nordisk is its people. We rely on the diversity of perspectives from colleagues all around the world. Our forward thinking, supported by careers that are as dynamic as we are, makes Novo Nordisk a great place to be and be from. This is your moment. Here we don’t stand still, we never give up – we make an impact. We’re trusted to have the courage. Together, we make it happen. To learn more, visit us at https://www.novonordisk-us.com/careers/find-a-job.html
1245 articles about Novo Nordisk
-
Novo Nordisk and TetraScience partner on a cloud-based instrument data platform
3/23/2021
Novo Nordisk A/S, a leading global healthcare company, and TetraScience, the leading global Life Sciences R&D Data Cloud, announce a new partnership to design a cloud-based instrument data platform for drug R&D, built natively on Amazon Web Services.
-
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
3/23/2021
Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention
-
The life sciences industry is a bustling beehive of activity. Here’s a quick compilation of some of today’s newsworthy announcements.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
3/18/2021
Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis.
-
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
-
Lilly’s tirzepatide has been proposed as a potentially effective treatment option that may rival the efficacy of semaglutide.
-
City of Mississauga welcomes new research hub in Mississauga funded by Novo Nordisk and University of Toronto aimed at reducing diabetes in community
2/25/2021
Yesterday, Novo Nordisk a global healthcare company with Canadian headquarters in Mississauga, and the University of Toronto announced a new research hub at U of T's Mississauga campus that will bring leading public health experts together to help reduce chronic illnesses across the globe.
-
Data published in the New England Journal of Medicine shows the once-weekly dose of the glucagon-like peptide-1 (GLP-1) analog significantly reduced weight in patients over the course of 68 weeks.
-
Cities Changing Diabetes announces five new programs to fight diabetes and obesity in Philadelphia
1/13/2021
Five innovative community-based programs have been selected to receive preliminary funding to help combat diabetes and obesity in Philadelphia through Cities Changing Diabetes.
-
Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com
1/4/2021
- COVID-19 Patient Assistance Program: Eligible patients can continue to enroll in our Diabetes Patient Assistance Program and receive a free 90-day supply of insulin until June 30, 2021 - My$99Insulin Program: Patients who enrolled in the cash card program in 2020 must reregister to determine if they are eligible to continue participating in 2021
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
It’s been a busy day so far for biopharma news and updates. Read on for more.
-
Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 Billion
12/8/2020
Emisphere Technologies, Inc. announced the completion of the previously announced transaction whereby Novo Nordisk A/S acquired Emisphere, on a cash-free, debt-free basis, for $1.35 billion.
-
FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17
12/5/2020
Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade
-
Gilead Sciences and Novo Nordisk presented data from a Phase II proof-of-concept clinical trial of semaglutide in combinations with cilofexor and/or firsocostat in non-alcoholic steatohepatitis.
-
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
11/15/2020
Results from First Phase 2 Trial Describing a Triple Combination Regimen Targeting NASH Presented at The Liver Meeting Digital Experience
-
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk and Emisphere have been partnered since 2007.
-
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
11/5/2020
Trial participants were adults with obesity or overweight with at least one weight-related co-morbidity and without type 2 diabetes.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.